GCAN Greater Cannabis Company Inc (PK)

Activity Initiated by Company and Dr. Nusbacher Filing Provisional Patent for Treatment of Avian Flu Utilizing IVIg Therapy Gammacan International (OTC BB:GCAN), a developer of immunotherapies for cancer and other diseases, today announced that Dr. Jacob Nusbacher has accepted an appointment as Medical Advisor to the Company to oversee the Phase II Clinical trial of GCAN 101 for the treatment of metastatic cancer and to expand the Company's pipeline in plasma-based products. The Company concurrently announced that in line with Dr. Nusbacher's mission of expanding Gammacan's platform of IVIg-based products it filed a Provisional Patent with the U.S. patent office for the utilization of IVIg therapy as a potential treatment for avian flu using IVIg from previously infected patients and from those previously immunized. IVIg has been efficacious in treating other viral diseases such as Hepatitis B, and Rabies. "Dr. Nusbacher's research and experience in hematology, immunology, and plasma coupled with his expertise in initiating and managing clinical trials is truly extraordinary and will be of great assistance to Gammacan as we continue our Phase II trial of GCAN 101 for the treatment of metastatic cancer," stated Vered Caplan, CEO. A major east coast publication, reported yesterday in an article focused on avian flu, "We know that viruses mutate and strike in unpredictable ways. It is plausible that this virus might mutate as has been predicted and that an epidemic - or even a pandemic - might result. Since we cannot predict exactly how, where, or when the virus might mutate, we need a response that is both preventative and adaptive." Vered Caplan, CEO, commented, "We believe that Dr. Nusbacher's expertise will be of great assistance in furthering the Company's product pipeline. Because of the serious public health hazard that avian flu could present, Gammacan is presently exploring the possibilities that IVIg may hold in this area." About Dr. Nusbacher Dr. Nusbacher is a leading expert in the field of immunohematology, and has extensive experience in both the scientific and business aspects of human plasma- derived therapies. Prior to joining GammaCan, he served as Medical Director of Kamada Ltd, a pharmaceutical company specializing in drugs manufactured from human plasma. He has also served as National Director of the Canadian Red Cross Blood Transfusion Service and has directed major regional blood centers in the United States and Canada. In addition, Dr. Nusbacher has held the position of Professor of Medicine at the Universities of Rochester, Pittsburgh and Toronto, and was Visiting Professor at Tel Aviv University. He has more than 100 scientific publications to his credit. Dr. Nusbacher has also served as a member of the first FDA Panel on Blood and Blood Products (BPAC) for five years and on the Editorial Board of the Journal Transfusion for 20 years. Dr. Nusbacher has and has designed and led clinical trials for a number of different drugs as part of the process in obtaining FDA approval. He has consulted for major U.S. companies including DuPont, Bayer, and Alpha Therapeutics. About GammaCan: GammaCan is focusing on the commercialization of a revolutionary anti-cancer immunotherapy that the Company believes will be proven to be effective in reducing the metastatic spread of a wide range of cancers. GammaCan's proposed treatment is based on IVIG, a safe, relatively non-toxic human plasma-based product, currently used to treat a variety of immune deficiencies and autoimmune diseases. It works by strengthening the patient's immune system. Many experts currently view immunotherapy as a future alternative to today's standard chemotherapy. Approximately twenty companies produce IVIG, and annual worldwide sales are currently in excess of 50 metric tones with an estimated value in excess of 1.5 billion USD. IVIG is commonly used to treat certain autoimmune diseases and blood disorders and to replace the antibodies in people who are unable to produce them. For more information about GammaCan visit www.gammacan.com or call the company's headquarters in Givat Shmuel, Israel at 972 3 5774475. Safe Harbor Statement: Statements in this document that are not purely historical are forward-looking statements. Forward-looking statements in this release include statements regarding: the commercialization of an anti-cancer immunotherapy and the Company developing the boosting of cancer patients' immune systems with IVIG into an effective treatment. Actual outcomes and the Company's actual results could differ materially from those in such forward-looking statements. Factors that could cause actual results to differ materially include risks and uncertainties such as the inability to finance the planned development of the technology, inability to hire appropriate staff to develop the technology, unforeseen technical difficulties in developing the technology, inability to obtain regulatory approval for human use, competitors' therapies proving more effective, cheaper or otherwise preferable for consumers, inability to market the product we produce, among other factors, all of which could among other things, delay or prevent product release or cause our company to fail. For further risk factors see the risk factors associated with other early stage medical research and development companies filed with the SEC on Edgar.